Researchers wanted to understand the relationship between the renoprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors and blood pressure (BP) in patients with low BP. They examined BP and urinary albumin:creatinine ratio data from patients with type 2 diabetes and chronic kidney disease before and after treatment. Lower BP was found to be associated with greater change in urinary albumin:creatinine ratio following treatment with SGLT2 inhibitors. The researchers concluded that stricter BP management is required to enhance the renoprotective effects of SGLT2 inhibitors.
Sign up to all DiabetesontheNet journals
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
NICE's updated guidance on type 2 diabetes: Implications for practice.
8 Mar 2022